Atezolizumab (anti-PD-L1)

目录号：A2004         批次号: A200410

打印

Atezolizumab (anti-PD-L1)是人源、IgG1单克隆抗体，阻止PD-L1与PD-1和B7.1的相互作用，但不影响PD-L2与PD-1的相互作用；MW：145 KD。

抗体信息

CAS号 1380723-44-3
配制 PBS buffer, pH 7.2
推荐同型对照 Human IgG1
来源 CHO cells
储存条件
(自收到货起)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
纯度 99%
蛋白浓度 13.03mg/ml
内毒素 ＜1EU/mg

客户使用selleck产品的实验数据

Atezolizumab (anti-PD-L1)在文献中得到引用

Favorable impact of PD1/PD-L1 antagonists on bone remodeling: an exploratory prospective clinical study and ex vivo validation [ J Immunother Cancer, 2024, 12(5)e008669] PubMed: 38702145
[ Int Immunopharmacol, 2024, ] PubMed: 38442580
Polymer-based antibody mimetics (iBodies) target human PD-L1 and function as a potent immune checkpoint blocker [ J Biol Chem, 2024, S0021-9258(24)01826-X] PubMed: 38685532
Pivotal role of myeloid-derived suppressor cells in infection-related tumor growth [ Cancer Med, 2024, 13(4):e6917] PubMed: 38457241
A novel ultrasensitive chemiluminescence enzyme immunoassay by employment of a signal enhancement of horseradish peroxidase-luminol-hydrogen peroxide reaction for the quantitation of atezolizumab, a monoclonal antibody used for cancer immunotherapy [ RSC Adv, 2024, 14(12):8167-8177] PubMed: 38469186
Acquired resistance to CDK4/6 inhibition is associated with dysregulation of multiple pathways including cyclin D-CDK4/6-RB, EGFR/HER, AKT/mTOR and IFN [ Research Square, 2024, 10.21203/rs.3.rs-3782509/v1] PubMed: none
Engineering high-affinity dual targeting cellular nanovesicles for optimised cancer immunotherapy [ J Extracell Vesicles, 2023, 12(11):e12379] PubMed: 37974395
YAP1 expression is associated with survival and immunosuppression in small cell lung cancer [ Cell Death Dis, 2023, 14(9):636] PubMed: 37752152
YAP1 expression is associated with survival and immunosuppression in small cell lung cancer [ Cell Death Dis, 2023, 14(9):636] PubMed: 37752152
Synergistically Enhancing Immunotherapy Efficacy in Glioblastoma with Gold-Core Silica-Shell Nanoparticles and Radiation [ Int J Nanomedicine, 2023, 18:7677-7693] PubMed: 38111846

禁止用于人体及治疗！